Cutting-Edge MS Clinical Trial: Led by a Visionary Black Physician

Historically, Black and Hispanic populations have experienced significant underrepresentation in clinical studies, especially concerning conditions like relapsing multiple sclerosis (RMS). To address this disparity, a groundbreaking two-year research initiative was launched to assess the safety and effectiveness of ocrelizumab among these communities.Led by Dr. Mitzi Joi Williams, an esteemed neurologist and founder of the Joi Life Wellness Group, the CHIMES (Characterization of Ocrelizumab in Minorities with Multiple Sclerosis) study focused on Black and Hispanic individuals diagnosed with RMS. The research, unveiled at the 2025 Consortium of Multiple Sclerosis Annual Meeting, yielded encouraging findings. Involving 182 participants—62% Black and 38% Hispanic—the study monitored treatment outcomes over a two-year period.Dr. Williams highlighted the significance of this research in addressing longstanding exclusion from clinical trials. Notably, nearly half of the Black participants reported no relapses, showcasing ocrelizumab’s capacity to reduce disease activity and enhance the quality of life for these historically underrepresented groups, marking a crucial leap forward in MS research.